bsm-61036R

[Primary Antibody]

www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

OGT Recombinant Rabbit mAb

DATASHEET -

Host: Rabbit Isotype: IgG **Clonality:** Recombinant CloneNo.: 7A5 **GeneID: 8473** SWISS: 015294

Target: OGT

Immunogen: A synthesized peptide derived from human OGT: 1000-1046.

Purification: affinity purified by Protein A

Storage: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Shipped at 4°C. Store at -20 °C for one year. Avoid repeated

freeze/thaw cycles.

Background: Addition of nucleotide-activated sugars directly onto the polypeptide through O-glycosidic linkage with the hydroxyl of serine or threonine.

Mediates the O-glycosylation of MLL5 and HCFC1. Promotes proteolytic maturation of HCFC1. Since both phosphorylation and glycosylation compete for similar serine or threonine residues, the two processes may compete for sites, or they may alter the substrate specificity of nearby sites by steric or electrostatic effects. O-GlcNAc transferase has been purified from rat liver. It exists as a heterotrimeric complex with two subunits of the same molecular mass and one shorter subunit. Both polypeptides are related; the short subunit band is either a proteolytic product of the polypeptide or the product of an alternative translation start site. O-GlcNAc transferase is expressed as multiple transcripts that are present in different amounts in various human tissues, with the highest levels of expression in pancreas. Immunofluorescence of human cells

expressing rat O-GlcNAc transferase indicated that it is present in both the nucleus and cytosol. HeLa cells expressing O-GlcNAc

transferase do not survive well during prolonged incubations, suggesting that this protein may be toxic to the cells.

Applications: WB (1:500-2000)

Reactivity: Human (predicted: Mouse,


Rat)

Predicted MW.:

Subcellular Cell membrane, Cytoplasm

Location: , Nucleus

VALIDATION IMAGES -



25 ug total protein per lane of various lysates (see on figure) probed with OGT monoclonal antibody, unconjugated (bsm-61036R) at 1:2000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.